Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

Home

/

CRIS

C

Curis, Inc. (CRIS)

NCM – Real vaqt narxi. Valyuta: USD

0.55

-0.00 (-0.11%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.58

+0.03 (5.11%)

Bozor oldidan: May 13, 2026, 7:55 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. (CRIS) Q1 2026 Earnings Call Transcript

Curis Provides First Quarter 2026 Business Update

Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026

LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter 2026 financial and operating results on Tuesday, May 12, 2026, at 4:00 p.m.

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates

Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago.

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?

Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript

Curis Provides Fourth Quarter 2025 Business Update

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Videolar

No Data

There is no data to display

Press-relizlar

Curis Provides First Quarter 2026 Business Update

Curis Provides First Quarter 2026 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Provides Fourth Quarter 2025 Business Update

19.03.2026

Curis Provides Fourth Quarter 2025 Business Update

Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds

LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.